Business of Aesthetics

Top Story

JAK inhibitors for hair loss receive US patents

September 5, 2017

The US patent office has issued two patents for janus kinase inhibitors for hair loss, according to a press release from Aclaris Therapeutics.

One of the patents includes coverage for tofacitinib, baricitinib (Olumiant, Incyte & Lilly), ruxolitinib (Jakafi, Incyte) and decernotinib (KareBay Biochem) as therapeutic options for androgenetic alopecia, or pattern hair loss. There are 22 claims in this patent, according to the statement.

Allergan reports Q2 net revenue increase

August 4, 2017
Allergan reported its second quarter 2017 operations performance, including total net revenues of $4 billion, which was a 9% increase from the same quarter a year…

Sienna Biopharmaceuticals closes initial public offering

August 2, 2017
Sienna Biopharmaceuticals announced the closing of its initial public offering of 4,983,333 shares of common stock at a public offering price of $15 per share. The…

Sientra, Silimed reach settlement on litigation on breast implant manufacturing

August 2, 2017
A settlement agreement was reached between Sientra Inc., a medical aesthetics corporation, and Silimed-Indústria de Implantes Ltda., the former contracted breast…
More Headlines »
Advertisement
Advertisement